GEOMX
LIVE

Serial Number

87982200

Owner

NanoString Technologies, Inc.

Attorney

Alyssa Worsham

First Use Date

Sep 3, 2019

Filing Date

May 9, 2018

Add to watchlist:

No watchlists yet
View on USPTO

GEOMX Trademark

Serial Number: 87982200 • Registration: 5945133

GEOMX is a trademark filed by NanoString Technologies, Inc. on May 9, 2018. The trademark is classified under Class 1 (Chemicals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

NanoString Technologies, Inc. (31 trademarks)

530 Fairview Avenue North, Suite 2000
Seattle, WA 98109

Entity Type: 03

BRUKER SPATIAL BIOLOGY, INC. (22 trademarks)

40 MANNING ROAD
BILLERICA, MA 01821

Entity Type: 03

Trademark Details

Filing Date

May 9, 2018

Registration Date

December 24, 2019

First Use Anywhere

September 3, 2019

First Use in Commerce

September 3, 2019

Published for Opposition

December 11, 2018

Goods & Services

clinical and medical diagnostic instruments, namely, histopathology instruments and nucleic acid sequencers; clinical and medical diagnostic instruments for analysis of tissue and/or cell based samples, all for medical purposes; clinical and medical diagnostic instruments for performing immunohistochemistry and in situ-hybridization staining reactions, histological and pathological staining and image processing and analysis; histopathology instruments for clinical purposes; clinical and medical diagnostic instruments for immunohistochemistry and in situ-hybridization analyses; clinical and medical diagnostic instruments for the electronic scanning of clinical pathology slides, processing and storing images of biological tissues and cells and digitizing, processing and storing images of biological tissues and cells

reagents and instruments for scientific, research or non-medical or veterinary diagnostic use in the fields of pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; diagnostic reagents for scientific or research use in the fields of cancer, neurology and infectious disease; reagents for scientific, research or non-medical or veterinary diagnostic use relating to molecular identification and digital quantification; reagents for scientific, research or non-medical or veterinary diagnostic use containing antibodies and nucleic acids; reagent kits comprising primarily reagents for scientific, research or non-medical or veterinary diagnostic use in the fields of cancer, neurology and infectious disease; reagents for immuno-histochemistry detection and in situ-hybridization detection for scientific, research or non-medical or veterinary diagnostic use; test kits for scientific, research or non-medical or veterinary diagnostic use comprising reagents, slides, solid matrix materials, microfluidic devices and support documentation, namely, instructional manuals, therefor; test kits comprising reagents for scientific, research or non-medical or veterinary diagnostic use relating to molecular identification and digital quantification; reagents for in vitro use in clinical chemistry and molecular biology; reagents for clinical or medical laboratory use, namely, reagents for pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling, nucleic acid sequencing, and clinical, oncology, neurology, and infectious disease diagnostics; multiparameter quantitative detection and analysis products and technology for research and diagnostics for a variety of uses in the health care and other life science sectors, namely, reagents for scientific or medical research use, diagnostic preparations and reagents for scientific or research uses, namely, pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; test kits, consisting of chemical preparations for scientific purposes, in particular for the detection, diagnosis, progress monitoring and progress prediction of diseases, including inflammations, infections, disorders of the central nervous systems, cardiovascular, neurological, endocrine, autoimmune and genetic disorders and cancers

automated apparatus in the nature of automated laboratory equipment and computer systems comprised of computer hardware and software for detection and analysis of biomolecules for scientific use; automated apparatus in the nature of automated laboratory equipment and computer systems comprised of computer hardware and software for scientific research, namely, for detecting, collecting and processing optical signals and images, into data for use in the analysis of biomolecules in connection with scientific or medical research; automated apparatus in the nature of automated laboratory equipment in the nature of digital imagers, digital displays, microscopes, robotics, fluidic stations and computer systems for staining and/or visualization of tissue or cell based samples for diagnostic or scientific use; automated apparatus in the nature of automated laboratory equipment in the nature of digital imagers, digital displays, microscopes, robotics and computer systems for digitizing images of biological tissue for use in connection with pathology; automated apparatus in the nature of automated laboratory equipment in the nature of digital imagers, digital displays, microscopes, robotics and computer systems for capturing digital images of microscope slides of biological tissue, storage of digitized microscope slide images in a data storage area, and display of digitized microscope slide images; automated apparatus in the nature of automated laboratory equipment in the nature of digital imagers, digital displays, microscopes, robotics, fluidic stations and computer systems comprised of computer hardware and software for detection and analysis of, pathology, gene expression, RNA transcription, RNA translation and nucleic acid sequencing; computer hardware and software to enable pathologists to diagnose disease; computer hardware and software for the electronic scanning of clinical pathology slides; computer hardware and software for pathologists to render and report diagnoses and results of scientific research; computer hardware and software for scientific or research uses, namely, pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription and microRNA expression profiling and nucleic acid sequencing; computer hardware and software for digitizing, processing and storing images of biological tissues and cells; computer hardware and software for analyzing the results of tissues and cell based samples obtained through operation of tissue and cell sample staining and visualization apparatus; computer hardware and software for identifying and diagnosing cancer and other diseases and processing digital images; computer hardware and software for viewing, analyzing, managing, reporting, and archiving digital images; laboratory equipment for sample preparation, mixing, hybridization, incubation, washing, location and imaging, namely, robotic equipment, fluid mixers, pumps, valves, and containers, reagent holders, sample containers and microfluidic devices, optical devices, scanning microscopes, fluorescent microscopes, digital micromirror devices, electromagnetic sensors and replacement parts therefor in the fields of scientific research; computer systems, namely, software and data files to acquire, analyze, manage and report biological information

research and product development services for others in the field of biotechnology; medical and scientific research services for others in the fields of pathology, immunohistochemistry, in situ-hybridization, proteomics, RNA transcription, RNA translation, gene expression profiling and nucleic acid sequencing; medical and scientific research in the field of cancer treatment and diagnosis; medical and scientific research services for others in the field of infectious disease; medical and scientific research services for others in the field of neurology; medical and scientific research services for others, namely, research and design in the field of testing, analyzing and examining biological samples, medical samples, and cell samples; providing laboratory research services for others in the field of gene expression and genetic data mining; research and development services for others for acquiring, analyzing, and managing biological and genetic information in the fields of diagnostic reagents, forensics, medicine, genetics, and environment; research, design, and development services for others in the fields of diagnostic reagents, compounds and devices, measuring apparatus for use in product research and development, separation and purification processes

Filing History

NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Mar 17, 2026 NA85
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Mar 17, 2026 C15A
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Mar 16, 2026 APRE
TEAS SECTION 8 & 15 RECEIVED
Dec 11, 2025 E815
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Dec 24, 2024 REM1
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Jul 4, 2024 ASGN
REGISTERED-PRINCIPAL REGISTER
Dec 24, 2019 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Nov 21, 2019 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Nov 20, 2019 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Oct 28, 2019 SUPC
DIVISIONAL PROCESSING COMPLETE
Oct 28, 2019 DPCC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 25, 2019 AITU
USE AMENDMENT FILED
Oct 23, 2019 IUAF
DIVISIONAL REQUEST RECEIVED
Oct 23, 2019 DRRR
TEAS REQUEST TO DIVIDE RECEIVED
Oct 23, 2019 ERTD
TEAS STATEMENT OF USE RECEIVED
Oct 23, 2019 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 3, 2019 EXRA
SOU EXTENSION 1 GRANTED
Oct 2, 2019 EX1G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Oct 2, 2019 AITU
NOTICE OF REVIVAL - E-MAILED
Aug 15, 2019 NREV
SOU EXTENSION RECEIVED WITH TEAS PETITION
Aug 15, 2019 TPEX
PETITION TO REVIVE-GRANTED
Aug 15, 2019 PETG
TEAS PETITION TO REVIVE RECEIVED
Aug 15, 2019 PROA
SOU EXTENSION 1 FILED
Aug 5, 2019 EXT1
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Feb 5, 2019 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 11, 2018 NPUB
PUBLISHED FOR OPPOSITION
Dec 11, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Nov 21, 2018 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Nov 2, 2018 PREV
ASSIGNED TO LIE
Nov 2, 2018 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Oct 18, 2018 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 15, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 14, 2018 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Oct 14, 2018 TROA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Aug 31, 2018 GPRN
PRIORITY ACTION E-MAILED
Aug 31, 2018 GPRA
PRIORITY ACTION WRITTEN
Aug 31, 2018 CPRA
ASSIGNED TO EXAMINER
Aug 30, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 18, 2018 NWOS
NEW APPLICATION ENTERED
May 12, 2018 NWAP